Research Antibodies Market
The small proteins known as antibodies, which are an essential component of immune system's reaction to diseases, are helpful in biomedical research. For decades, researchers have been developing antibodies to fight and understand viruses like Covid-19 and many common infectious disorders. The majority of antibodies used in research are referred to as "animal-derived" and are obtained from animals. A small quantity of the desired foreign antigen is injected into an animal. This triggers the immune system to generate antibodies in defense. These are then collected for use in research, either from the spleen or the blood.
Market Dynamics
Increasing collaborations and partnerships in market players is expected to witness significant growth in forecast period. For instance, in March 2022, Sanofi, a French multinational pharmaceutical and healthcare company and Seagen Inc., an American biotechnology company announced an exclusive collaboration agreement to design, develop, and market antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will make use of the exclusive monoclonal antibody (mAb) technology from Sanofi and the exclusive ADC technology from Seagen. Sanofi is now working on an ADC, which is an antibody designed to carry powerful anti-cancer medications to tumor cells expressing a certain protein.
Increasing product launches by market players are expected to drive growth of the global research antibodies market over the forecast period. For instance, in April 2019, ImmunoPrecise, a full-service, therapeutic antibody discovery company launched DeepDisplay, Antibody Discovery Platform with an unknown U.S. based Pharma Company. In contrast to conventional technologies, DeepDisplay uses a transgenic animal immunization combined with phage display antibody selection to deliver the most therapeutically-relevant antibodies in the shortest amount of time with the highest chances of success.
Increasing product approvals are expected to drive growth of market over the forecast period. For instance, in April 2021, Gilead Sciences Inc., an American biopharmaceutical company announced that Trodelvy (sacituzumab govitecan-hziy), for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer, has received full approval from the U.S. Food and Drug Administration (FDA). Trodelvy (sacituzumab govitecan-hziy) is an antibody–drug conjugate that combines a humanized monoclonal antibody.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Detailed Segmentation:
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowWe help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail
Request Discount
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients